贝伐单抗联合紫杉醇治疗复发性卵巢癌及病理组织中斯钙素1表达和预后的关系  

Betazide combined with taxol in the treatment of recurrent ovarian cancer and the relationship between pathological tissues stanniocalcin 1 expression and prognosis

作　　者：孙鹏程 赵晶 刘广芝 SUN Peng-cheng;ZHAO Jing';LIU Guang-zhi(Department of Obstetrics and Gynecology,People,s Hospital of Zhengzhou University,Zhengzhou 450003,Henan Province,China;Microbiome Laboratory,Henan People's Hospital,Zhengzhou 450003,Henan Province,China)

机构地区：[1]郑州大学人民医院妇产科,河南郑州450003 [2]河南省人民医院微生物组学实验室,河南郑州450003

出　　处：《中国临床药理学杂志》2019年第22期2819-2822,共4页The Chinese Journal of Clinical Pharmacology

摘　　要：目的观察贝伐单抗联合紫杉醇治疗复发性卵巢癌的疗效,分析卵巢癌组织斯钙素1(STC1)表达与患者预后的关系。方法回顾性分析60例复发性卵巢癌患者的临床资料,均以贝伐单抗(15 mg·kg^-1,静脉滴注)联合紫杉醇(175mg·m^-2,静脉滴注)治疗,3周为1个治疗周期,连续治疗4个周期,所有患者均定期随访3年。统计2组患者临床疗效,以免疫组化法检测化疗前患者卵巢癌组织STC1表达情况,分析其与患者临床特征、临床疗效及预后的关系。结果治疗后,60例复发性卵巢癌患者缓解率(RR)为61.67%(37例/60例),疾病控制率(DCR)为83.33%(50例/60例),卵巢癌组织中STC1蛋白阳性表达率为48.33%(29例/60例),且浆液性卵巢癌患者、卵巢癌分期为Ⅲ~Ⅳ期患者及病理分级为G3级患者卵巢癌组织STC1蛋白阳性患者比例分别高于黏液性卵巢癌患者、卵巢癌分期为Ⅰ~Ⅱ期患者及病理分级为G1~G2级患者(P<0.05或P<0.01);STC1阳性患者RR、DCR及3年生存率均显著低于STC1阴性患者(P<0.05),且STC1阳性患者PFS较STC1阴性患者短(P<0.05)。Spearman相关性分析显示,STC1蛋白阳性表达与患者RR,DCR,3年生存率及PFS均呈负相关(r=-0.521;-0.603;0.469;0.618,P<0.05)。结论贝伐单抗联合紫杉醇对复发性卵巢癌患者具有一定的化疗疗效,且卵巢癌组织STC1表达与患者化疗疗效及预后呈明显负相关。Objective To explore the clinical effect of betazide combined with taxol in the treatment of recurrent ovarian cancer,and analyse the relationship between pathological tissues stanniocalcin 1(STC1)expression and prognosis.Methods The clinical data of 60 cases recurrent ovarian cancer patients were carried retrospective analysis,they were treated with betazide(15 mg·kg^-1,intravenous dripping)combined with taxol(175 mg·m^-2,intravenous dripping),3 weeks were for 1 treatment cycle,and treated for 4 continuous cycles,all patients were followed-up for 3 years regularly.The clinical effect of patients in two groups were statisticed,the ovarian cancer tissue STC1 expression of patients before chemotherapy was detected by immunohistochemical method,analysed the relationship between which and clinical characteristics,clinical curative effect and prognosis.Results The response rate(RR)of 60 cases recurrent ovarian cancer patients aftertreatment was 61.67%(37 cases/60 cases),disease control rate(DCR)was 83.33%(50 cases/60 cases);the STC1 protein positive expression in ovarian cancer tissue was 48.33%(29 cases/60 cases),the proportion of patients with STC1 protein positive expression of serous ovarian cancer patients,patients with ovarian cancer staging Ⅲ-Ⅳ stage and patients with pathology classification G3 were higher than mucous ovarian cancer patients,patients with ovarian cancer staging Ⅰ-Ⅱstage and patients with pathology classification G1-G2(P<0.05);the RR,DCR and 3-year-survival rate of patients with STC1 positive expression were lower than those patients with STC1 negative(P<0.05),and the progression-free survival(PFS)of patients with STC1 positive expression was shorter than patients with STC1 negative expression(P<0.05);Spearman correlation analysis showed that,the STC1 protein positive expression had significant negative correlation with RR,DCR,3-year-survival rate and PFS(r=-0.521;-0.603;0.469;0.618,P<0.05).Conclusion Betazide combined with taxol has certain chemotherapy curative effect for ecurrent o

关 键 词：复发性卵巢癌 贝伐单抗 紫杉醇 斯钙素1 表达 预后 

分 类 号：R979.1[医药卫生—药品]